Inhibition of Angiogenesis and Vascular Leakiness by Angiopoietin-Related Protein 4

Yasuhiro Ito, Yuichi Oike, Kunio Yasunaga, Koichi Hamada, Keishi Miyata, Shun Ichiro Matsumoto, Sumio Sugano, Hidenobu Tanihara, Yasuhiko Masuho, Toshio Suda

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Angiopoietins and angiopoietin-related proteins (ARPs) have been shown to regulate angiogenesis, a process essential for various neovascular diseases including tumors. Here, we identify ARP4/fasting-induced adipose factor/peroxisome proliferator-activated receptor γ angiopoietin-related as a novel antiangiogenic modulatory factor. We hypothesized that ARP4 may regulate angiogenesis. In vitro experiments using purified recombinant ARP4 protein revealed that ARP4 markedly inhibited the proliferation, chemotaxis, and tubule formation of endothelial cells. Moreover, using corneal neovascularization and Miles permeability assays, we found that both vascular endothelial growth factor-induced in vivo angiogenesis and vascular leakiness were significantly inhibited by the addition of ARP4. Finally, we found remarkable suppression of tumor growth within the dermal layer associated with decreased numbers of invading blood vessels in transgenic mice that express ARP4 in the skin driven by the keratinocyte promoter. These findings demonstrate that ARP4 functions as a novel antiangiogenic modulatory factor and indicate a potential therapeutic effect of ARP4 in neoplastic diseases.

Original languageEnglish
Pages (from-to)6651-6657
Number of pages7
JournalCancer Research
Volume63
Issue number20
Publication statusPublished - 2003 Oct 15

Fingerprint

Angiopoietins
Blood Vessels
Corneal Neovascularization
Skin
Peroxisome Proliferator-Activated Receptors
Proteins
Therapeutic Uses
Chemotaxis
Keratinocytes
Recombinant Proteins
Vascular Endothelial Growth Factor A
Transgenic Mice
Permeability
Fasting
Neoplasms
Endothelial Cells
Growth
Inhibition (Psychology)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ito, Y., Oike, Y., Yasunaga, K., Hamada, K., Miyata, K., Matsumoto, S. I., ... Suda, T. (2003). Inhibition of Angiogenesis and Vascular Leakiness by Angiopoietin-Related Protein 4. Cancer Research, 63(20), 6651-6657.

Inhibition of Angiogenesis and Vascular Leakiness by Angiopoietin-Related Protein 4. / Ito, Yasuhiro; Oike, Yuichi; Yasunaga, Kunio; Hamada, Koichi; Miyata, Keishi; Matsumoto, Shun Ichiro; Sugano, Sumio; Tanihara, Hidenobu; Masuho, Yasuhiko; Suda, Toshio.

In: Cancer Research, Vol. 63, No. 20, 15.10.2003, p. 6651-6657.

Research output: Contribution to journalArticle

Ito, Y, Oike, Y, Yasunaga, K, Hamada, K, Miyata, K, Matsumoto, SI, Sugano, S, Tanihara, H, Masuho, Y & Suda, T 2003, 'Inhibition of Angiogenesis and Vascular Leakiness by Angiopoietin-Related Protein 4', Cancer Research, vol. 63, no. 20, pp. 6651-6657.
Ito Y, Oike Y, Yasunaga K, Hamada K, Miyata K, Matsumoto SI et al. Inhibition of Angiogenesis and Vascular Leakiness by Angiopoietin-Related Protein 4. Cancer Research. 2003 Oct 15;63(20):6651-6657.
Ito, Yasuhiro ; Oike, Yuichi ; Yasunaga, Kunio ; Hamada, Koichi ; Miyata, Keishi ; Matsumoto, Shun Ichiro ; Sugano, Sumio ; Tanihara, Hidenobu ; Masuho, Yasuhiko ; Suda, Toshio. / Inhibition of Angiogenesis and Vascular Leakiness by Angiopoietin-Related Protein 4. In: Cancer Research. 2003 ; Vol. 63, No. 20. pp. 6651-6657.
@article{8b80b8374ee7445fa8cd9b2dff89fb74,
title = "Inhibition of Angiogenesis and Vascular Leakiness by Angiopoietin-Related Protein 4",
abstract = "Angiopoietins and angiopoietin-related proteins (ARPs) have been shown to regulate angiogenesis, a process essential for various neovascular diseases including tumors. Here, we identify ARP4/fasting-induced adipose factor/peroxisome proliferator-activated receptor γ angiopoietin-related as a novel antiangiogenic modulatory factor. We hypothesized that ARP4 may regulate angiogenesis. In vitro experiments using purified recombinant ARP4 protein revealed that ARP4 markedly inhibited the proliferation, chemotaxis, and tubule formation of endothelial cells. Moreover, using corneal neovascularization and Miles permeability assays, we found that both vascular endothelial growth factor-induced in vivo angiogenesis and vascular leakiness were significantly inhibited by the addition of ARP4. Finally, we found remarkable suppression of tumor growth within the dermal layer associated with decreased numbers of invading blood vessels in transgenic mice that express ARP4 in the skin driven by the keratinocyte promoter. These findings demonstrate that ARP4 functions as a novel antiangiogenic modulatory factor and indicate a potential therapeutic effect of ARP4 in neoplastic diseases.",
author = "Yasuhiro Ito and Yuichi Oike and Kunio Yasunaga and Koichi Hamada and Keishi Miyata and Matsumoto, {Shun Ichiro} and Sumio Sugano and Hidenobu Tanihara and Yasuhiko Masuho and Toshio Suda",
year = "2003",
month = "10",
day = "15",
language = "English",
volume = "63",
pages = "6651--6657",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Inhibition of Angiogenesis and Vascular Leakiness by Angiopoietin-Related Protein 4

AU - Ito, Yasuhiro

AU - Oike, Yuichi

AU - Yasunaga, Kunio

AU - Hamada, Koichi

AU - Miyata, Keishi

AU - Matsumoto, Shun Ichiro

AU - Sugano, Sumio

AU - Tanihara, Hidenobu

AU - Masuho, Yasuhiko

AU - Suda, Toshio

PY - 2003/10/15

Y1 - 2003/10/15

N2 - Angiopoietins and angiopoietin-related proteins (ARPs) have been shown to regulate angiogenesis, a process essential for various neovascular diseases including tumors. Here, we identify ARP4/fasting-induced adipose factor/peroxisome proliferator-activated receptor γ angiopoietin-related as a novel antiangiogenic modulatory factor. We hypothesized that ARP4 may regulate angiogenesis. In vitro experiments using purified recombinant ARP4 protein revealed that ARP4 markedly inhibited the proliferation, chemotaxis, and tubule formation of endothelial cells. Moreover, using corneal neovascularization and Miles permeability assays, we found that both vascular endothelial growth factor-induced in vivo angiogenesis and vascular leakiness were significantly inhibited by the addition of ARP4. Finally, we found remarkable suppression of tumor growth within the dermal layer associated with decreased numbers of invading blood vessels in transgenic mice that express ARP4 in the skin driven by the keratinocyte promoter. These findings demonstrate that ARP4 functions as a novel antiangiogenic modulatory factor and indicate a potential therapeutic effect of ARP4 in neoplastic diseases.

AB - Angiopoietins and angiopoietin-related proteins (ARPs) have been shown to regulate angiogenesis, a process essential for various neovascular diseases including tumors. Here, we identify ARP4/fasting-induced adipose factor/peroxisome proliferator-activated receptor γ angiopoietin-related as a novel antiangiogenic modulatory factor. We hypothesized that ARP4 may regulate angiogenesis. In vitro experiments using purified recombinant ARP4 protein revealed that ARP4 markedly inhibited the proliferation, chemotaxis, and tubule formation of endothelial cells. Moreover, using corneal neovascularization and Miles permeability assays, we found that both vascular endothelial growth factor-induced in vivo angiogenesis and vascular leakiness were significantly inhibited by the addition of ARP4. Finally, we found remarkable suppression of tumor growth within the dermal layer associated with decreased numbers of invading blood vessels in transgenic mice that express ARP4 in the skin driven by the keratinocyte promoter. These findings demonstrate that ARP4 functions as a novel antiangiogenic modulatory factor and indicate a potential therapeutic effect of ARP4 in neoplastic diseases.

UR - http://www.scopus.com/inward/record.url?scp=0142188732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142188732&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 6651

EP - 6657

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 20

ER -